<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MESNEX- mesna injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MESNEX safely and effectively.  See full prescribing information for MESNEX. <br><br>MESNEX (mesna) injection, for intravenous use<br>MESNEX (mesna) tablets, for oral use<br>Initial U.S. Approval: 1988</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">MESNEX is a cytoprotective agent indicated as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> agent in reducing the incidence of ifosfamide-induced <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. (<a href="#i4i_indications_id_b6b830d5-b851-4a06-99a9-832115214015">1</a>) </p>
<p class="Highlighta"><span class="Underline">Limitation of Use: </span> </p>
<p class="Highlighta">MESNEX is not indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> due to other pathological conditions such as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. (<a href="#i4i_indications_id_b6b830d5-b851-4a06-99a9-832115214015">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX Tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered.  When the dosage of ifosfamide is adjusted, the ratio of MESNEX to ifosfamide should be maintained. (<a href="#i4i_dosage_admin_id_491e0543-b71f-4f9f-a14b-dbbc55b91bbd">2</a>) </p>
<a name="_RefID8C8F3C91AB414C2DB88D7BC4D6A06F2C"></a><table width="100%">
<caption><span>Intravenous Dosing Schedule: </span></caption>
<col width="32%">
<col width="16%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="Highlighta">0 Hours </p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="Highlighta">4 Hours </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="Highlighta">8 Hours </p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="Highlighta">Ifosfamide </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">1.2 g/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">-- </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">-- </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="Highlighta">MESNEX Injection </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">240 mg/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">240 mg/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">240 mg/m<span class="Sup">2</span> </p></td>
</tr>
</tbody>
</table>
<a name="_RefID82EB34C83D2746279400FC0CFE8BC7B4"></a><table width="100%">
<caption><span>Intravenous and Oral Dosing Schedule: </span></caption>
<col width="31%">
<col width="17%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="Highlighta">0 Hours </p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="Highlighta">2 Hours </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="Highlighta">6 Hours </p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="Highlighta">Ifosfamide </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">1.2 g/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">-- </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">-- </p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="Highlighta">MESNEX Injection </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">240 mg/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">-- </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">-- </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="Highlighta">MESNEX Tablets </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">-- </p></td>
<td class="Botrule Lrule" align="center"><p class="Highlighta">480 mg/m<span class="Sup">2</span> </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="Highlighta">480 mg/m<span class="Sup">2</span> </p></td>
</tr>
</tbody>
</table>
<p class="Highlighta">Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>. (<a href="#i4i_section_id_1e17fdb1-8c95-4616-b0db-a09803d3865f">2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Injection: 1g (100 mg/mL) Multidose vials (<a href="#i4i_dosage_form_strength_id_353dc7ad-f95c-41c8-9f75-09713e3d5194">3</a>)</dd>
<dt>•</dt>
<dd>Tablets: 400 mg with functional score (<a href="#i4i_dosage_form_strength_id_353dc7ad-f95c-41c8-9f75-09713e3d5194">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to MESNEX or to any of the excipients, including benzyl alcohol. (<a href="#i4i_contraindications_id_6d1850f8-2feb-4656-8bd6-50fc3f23ab30">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported. Less severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may also occur. Monitor patients. If a reaction occurs, discontinue MESNEX and provide supportive care. (<a href="#i4i_section_id_8aaa863d-6787-4cf2-9ddf-0f1abe57f5c9">5.1</a>)</dd>
<dt>•</dt>
<dd>Dermatologic toxicity: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have occurred. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have also been seen. Monitor patients. If a reaction occurs, discontinue MESNEX and provide supportive care. (<a href="#i4i_section_id_60147a96-f663-41b1-8040-a16f4ead3dbd">5.2</a>) </dd>
<dt>•</dt>
<dd>Benzyl alcohol toxicity: The preservative benzyl alcohol has been associated with serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in neonates and premature infants. Avoid use in neonates,  premature, and low-birth weight infants. (<a href="#i4i_section_id_166aadbb-0b04-4042-b51d-41c2e1f6959d">5.3</a>) </dd>
<dt>•</dt>
<dd>Laboratory test alterations: False positive tests for urinary <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> and interference with enzymatic CPK activity tests have been seen. (<a href="#i4i_section_id_addf37a2-508e-4dad-9e73-c405a1cfa0f6">5.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt; 10%) when MESNEX is given with ifosfamide are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. (<a href="#i4i_section_id_3efd4704-532d-43f4-a835-8aa13f93b994">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472, or FDA at 1-800-FDA-1088 or <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Use only if clearly needed. (<a href="#i4i_pregnancy_id_fffa14da-3ea4-4ef6-89b6-a20b7d711e3a">8.1</a>)</dd>
<dt>•</dt>
<dd>Nursing mothers: Women should not breastfeed during therapy. (<a href="#i4i_nursing_mothers_id_d15a8a67-9c49-417f-98df-cc897aa71b51">8.3</a>)</dd>
<dt>•</dt>
<dd>Geriatric use: Dose selection should be cautious. (<a href="#i4i_geriatric_use_id_ce63a95e-a4d9-4ed1-957b-be91bfaf6fe9">8.5</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Intravenous Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Intravenous and Oral Dosing</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Monitoring for <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation for Intravenous Administration and Stability</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Dermatologic Toxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Benzyl Alcohol Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Laboratory Test Interferences</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use in Patients with a History of Adverse Reactions to Thiol Compounds</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Intravenous MESNEX</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Oral MESNEX</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b6b830d5-b851-4a06-99a9-832115214015"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">MESNEX is indicated as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> agent in reducing the incidence of ifosfamide-induced <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.</p>
<p><span class="Underline">Limitation of Use: </span><br>MESNEX is not indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> due to other pathological conditions such as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_491e0543-b71f-4f9f-a14b-dbbc55b91bbd"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e198bf9f-335d-4728-847d-37fed48c7fc3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Intravenous Dosing</h2>
<p class="First">MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.</p>
<p>MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of MESNEX is 60% of the ifosfamide dose. The recommended dosing schedule is outlined below in Table 1.</p>
<a name="_RefID7050513770844753922DF3610D301BE2"></a><table width="100%">
<caption><span>Table 1. Recommended Intravenous Dosing Schedule </span></caption>
<col width="37%">
<col width="23%">
<col width="21%">
<col width="20%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is increased or decreased, the ratio of MESNEX to ifosfamide should be maintained.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">0 Hours</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">4 Hours</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">8 Hours</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Ifosfamide</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.2 g/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">–</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">MESNEX Injection</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">240 mg/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">240 mg/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">240 mg/m<span class="Sup">2</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_beca2f88-e0cd-4d9b-9424-b79bea6efd7d"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Intravenous and Oral Dosing</h2>
<p class="First">MESNEX may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below.</p>
<p>MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. MESNEX tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of MESNEX is 100% of the ifosfamide dose. The recommended dosing schedule is outlined in Table 2.</p>
<a name="_RefIDDC041E0E5CED4786A6D6AB5B04FE60BD"></a><table width="100%">
<caption><span>Table 2.  Recommended Intravenous and Oral Dosing Schedule </span></caption>
<col width="30%">
<col width="25%">
<col width="23%">
<col width="22%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is increased or decreased, the ratio of MESNEX to ifosfamide should be maintained.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">0 Hours</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">2 Hours</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">6 Hours</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Ifosfamide</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1.2 g/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">–</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">MESNEX injection</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">240 mg/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">–</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">–</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="Bold">MESNEX tablets</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">–</p></td>
<td class="Botrule Lrule" align="center"><p class="First">480 mg/m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">480 mg/m<span class="Sup">2</span></p></td>
</tr>
</tbody>
</table>
<p>The efficacy and safety of this ratio of intravenous and oral MESNEX has not been established as being effective for daily doses of ifosfamide higher than 2 g/m<span class="Sup">2</span>. </p>
<p>Patients who vomit within two hours of taking oral MESNEX should repeat the dose or receive intravenous MESNEX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e17fdb1-8c95-4616-b0db-a09803d3865f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Monitoring for <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></h2>
<p class="First">Maintain adequate hydration and sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>. If severe <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> develops when MESNEX is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93bbc48c-56eb-4b2c-90c5-77e83f5e4a07"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation for Intravenous Administration and Stability</h2>
<p class="First"><span class="Underline">Preparation</span></p>
<p>Determine the volume of MESNEX injection for the intended dose.</p>
<p>Dilute the volume of MESNEX injection for the dose in any of the following fluids to obtain a final concentration of 20 mg/mL:</p>
<dl>
<dt>•</dt>
<dd>5% Dextrose Injection, USP</dd>
<dt>•</dt>
<dd>5% Dextrose and 0.2% Sodium Chloride Injection, USP</dd>
<dt>•</dt>
<dd>5% Dextrose and 0.33% Sodium Chloride Injection, USP</dd>
<dt>•</dt>
<dd>5% Dextrose and 0.45% Sodium Chloride Injection, USP</dd>
<dt>•</dt>
<dd>0.9% Sodium Chloride Injection, USP</dd>
<dt>•</dt>
<dd>Lactated Ringer’s Injection, USP</dd>
</dl>
<p><span class="Underline">Stability</span></p>
<p>The MESNEX injection multidose vials may be stored and used for up to 8 days after initial puncture.</p>
<p>Store diluted solutions at 25°C (77°F). Use diluted solutions within 24 hours.</p>
<p>Do not mix MESNEX injection with epirubicin, cyclophosphamide, cisplatin, carboplatin, and nitrogen mustard.</p>
<p>The benzyl alcohol contained in MESNEX injection vials can reduce the stability of ifosfamide. Ifosfamide and MESNEX may be mixed in the same bag provided the final concentration of ifosfamide does not exceed 50 mg/mL.  Higher concentrations of ifosfamide may not be compatible with MESNEX and may reduce the stability of ifosfamide.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  Any solutions which are discolored, hazy, or contain visible particulate matter should not be used.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_353dc7ad-f95c-41c8-9f75-09713e3d5194"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd>MESNEX injection: 1 g Multidose Vial, 100 mg/mL </dd>
<dt>•</dt>
<dd>MESNEX tablets: 400 mg film-coated tablets with functional score</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6d1850f8-2feb-4656-8bd6-50fc3f23ab30"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">MESNEX is contraindicated in patients known to be hypersensitive to MESNEX or to any of the excipients [see <a href="#i4i_section_id_8aaa863d-6787-4cf2-9ddf-0f1abe57f5c9">Warnings and Precautions (5.1)</a>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_bee08736-7b37-4906-9768-dbc7d908531f"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8aaa863d-6787-4cf2-9ddf-0f1abe57f5c9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">MESNEX may cause systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. These reactions may include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, cardiovascular symptoms (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>), acute <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, laboratory signs of <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, hematological abnormalities, increased liver enzymes, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. These reactions may occur with the first exposure or after several months of exposure. Monitor for signs or symptoms. Discontinue MESNEX and provide supportive care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60147a96-f663-41b1-8040-a16f4ead3dbd"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Dermatologic Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">Drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms and bullous and ulcerative skin and mucosal reactions, consistent with <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> or <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have occurred. MESNEX may cause skin and mucosal reactions characterized by <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>. These reactions may occur with the first exposure or after several months of exposure. Discontinue MESNEX and provide supportive care. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_166aadbb-0b04-4042-b51d-41c2e1f6959d"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Benzyl Alcohol Toxicity</h2>
<p class="First">Benzyl alcohol, a preservative in MESNEX, has been associated with serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome) in neonates, premature, and low-birth weight infants. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Consider the combined daily metabolic load of benzyl alcohol from all sources when prescribing MESNEX (10.4 mg benzyl alcohol per mL). Neonates, premature, and low-birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Monitor patients for signs or symptoms of toxicity. Avoid use in neonates, premature, and low-birth weight infants. [See <a href="#i4i_pediatric_use_id_1c8c447f-fd76-498c-a370-52ba2e67fd6c">Use in Specific Populations (8.4)</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_addf37a2-508e-4dad-9e73-c405a1cfa0f6"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Laboratory Test Interferences</h2>
<p class="First"><span class="Italics">False-Positive Urine Tests for <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">Ketone Bodies</span></span></p>
<p>A false positive test for urinary <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> may arise in patients treated with MESNEX when using nitroprusside sodium-based urine tests (including dipstick tests).  The addition of glacial acetic acid can be used to differentiate between a false positive result (cherry-red color that fades) and a true positive result (red-violet color that intensifies).</p>
<p><span class="Italics">False-Negative Tests for Enzymatic CPK Activity </span></p>
<p>MESNEX may interfere with enzymatic creatinine phosphokinase (CPK) activity tests that use a thiol compound (e.g., N-acetylcysteine) for CPK reactiviation. This may result in a falsely low CPK level.</p>
<p><span class="Italics">False-Positive Tests for Ascorbic Acid </span></p>
<p>MESNEX may cause false-positive reactions in Tillman’s reagent-based urine screening tests for ascorbic acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_741f923a-14ad-4a0f-bf41-6946cd2d0434"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use in Patients with a History of Adverse Reactions to Thiol Compounds</h2>
<p class="First">MESNEX is a thiol compound, i.e., a sulfhydryl (SH) group-containing organic compound. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to MESNEX and to amifostine, another thiol compound, have been reported. It is not clear whether patients who experienced an adverse reaction to a thiol compound are at increased risk for a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to MESNEX.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_3cf2b16d-9e9c-4613-9dc1-82fa2a476dea"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following are discussed in more detail in other sections of the labeling.</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> [see <a href="#i4i_section_id_8aaa863d-6787-4cf2-9ddf-0f1abe57f5c9">Warnings and Precautions (5.1)</a>]</dd>
<dt>•</dt>
<dd>Dermatological Toxicity [see <a href="#i4i_section_id_60147a96-f663-41b1-8040-a16f4ead3dbd">Warnings and Precautions (5.2)</a>]</dd>
<dt>•</dt>
<dd>Benzyl Alcohol Toxicity [see <a href="#i4i_section_id_166aadbb-0b04-4042-b51d-41c2e1f6959d">Warnings and Precautions (5.3)</a>]</dd>
<dt>•</dt>
<dd>Laboratory Test Interferences [see <a href="#i4i_section_id_addf37a2-508e-4dad-9e73-c405a1cfa0f6">Warnings and Precautions (5.4)</a>]</dd>
<dt>•</dt>
<dd>Use in Patients with a History of Adverse Reactions to Thiol Compounds [see <a href="#i4i_section_id_741f923a-14ad-4a0f-bf41-6946cd2d0434">Warnings and Precautions (5.5)</a>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3efd4704-532d-43f4-a835-8aa13f93b994"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>MESNEX adverse reaction data are available from four Phase 1 studies in which single intravenous doses of 600-1200 mg MESNEX Injection without concurrent chemotherapy were administered to a total of 53 healthy volunteers and single oral doses of 600-2400 mg of MESNEX Tablets were administered to a total of 82 healthy volunteers. The most frequently reported side effects (observed in two or more healthy volunteers) for healthy volunteers receiving single doses of MESNEX Injection alone were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>. In two Phase 1 multiple-dose studies where healthy volunteers received MESNEX Tablets alone or intravenous MESNEX followed by repeated doses of MESNEX Tablets, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> were reported. In addition, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> was reported by healthy volunteers who had received repeated doses of intravenous MESNEX.</p>
<p>Additional adverse reactions in healthy volunteers receiving MESNEX alone included <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>/burning, mucosal irritation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4330445" conceptname="Pleuritic pain">pleuritic pain</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>. In healthy volunteers, MESNEX was commonly associated with a rapid (within 24 hours) decrease in lymphocyte count, which was generally reversible within one week of administration.</p>
<p>Because MESNEX is used in combination with ifosfamide or ifosfamide-containing chemotherapy regimens, it is difficult to distinguish the adverse reactions which may be due to MESNEX from those caused by the concomitantly administered cytotoxic agents.</p>
<p>Adverse reactions reasonably associated with MESNEX administered intravenously and orally in four controlled studies in which patients received ifosfamide or ifosfamide-containing regimens are presented in Table 3.</p>
<a name="_RefIDE6FA9469B0974A7DBE0E91EFA3461940"></a><table width="100%">
<caption><span>Table 3: Adverse Reactions in ≥ 5% of Patients Receiving MESNEX in combination with Ifosfamide-containing Regimens </span></caption>
<col width="25%">
<col width="45%">
<col width="30%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Intravenous dosing of ifosfamide and MESNEX followed by either intravenous or oral doses of MESNEX according to the applicable dosage schedule.  [see <a href="#i4i_dosage_admin_id_491e0543-b71f-4f9f-a14b-dbbc55b91bbd">Dosage and Administration (2)</a>]</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First">MESNEX Regimen</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">Intravenous-Intravenous-Intravenous<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Intravenous-Oral-Ora<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">N exposed</p></td>
<td class="Botrule Lrule" align="center"><p class="First">119 (100.0%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">119 (100%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Incidence of AEs</p></td>
<td class="Botrule Lrule" align="center"><p class="First">101 (84.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">106 (89.1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">65 (54.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64 (53.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">35 (29.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45 (37.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">28 (23.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21 (17.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 (21.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21 (17.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">24 (20.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24 (20.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">24 (20.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18 (15.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">21 (17.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">19 (16.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">21 (17.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16 (13.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">20 (16.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21 (17.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">16 (13.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15 (12.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">15 (12.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">21 (17.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">14 (11.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18 (15.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> </p></td>
<td class="Botrule Lrule" align="center"><p class="First">12 (10.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13 (10.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">11 (9.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (9.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 (8.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (9.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">10 (8.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (9.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (7.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">17 (14.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (7.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (4.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (7.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13 (10.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (7.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (8.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9 (7.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (1.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (5.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reaction</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (8.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (7.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Peripheral</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8 (6.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">8 (6.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12 (10.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">7 (5.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 (3.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">7 (5.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">6 (5.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (4.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">6 (5.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (9.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">5 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (8.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 (3.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 (3.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 (3.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">3 (2.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (5.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2 (1.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8 (6.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (5.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6 (5.0)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e1f767c-a647-4022-8d8c-5358dc3ff9fa"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported in the postmarketing experience of patients receiving MESNEX in combination with ifosfamide or similar drugs, making it difficult to distinguish the adverse reactions which may be due to MESNEX from those caused by the concomitantly administered cytotoxic agents. Because these reactions are reported from a population of unknown size, precise estimates of frequency cannot be made.</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p>
<p>Hepatobiliary: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></p>
<p>Nervous System: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span></p>
<p>Respiratory: <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_94a669ca-eaba-4689-9cc5-a32bfb272ddd"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No clinical drug interaction studies have been conducted with MESNEX.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_b60ac5eb-0c33-48b5-b1df-70f432f6379b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_fffa14da-3ea4-4ef6-89b6-a20b7d711e3a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_id_5d1d140b-364e-4030-b827-6dc9bf96bf6d"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category B.</h3>
<p class="First"><span class="Italics"><span class="Underline">Risk Summary</span></span></p>
<p>There are no studies of MESNEX in pregnant women. Reproduction studies performed in rats and rabbits at oral doses approximately 10 times the maximum recommended total daily intravenous-oral-oral human dose on a body surface area basis (1000 mg/kg in rabbits and 2000 mg/kg in rats) revealed no evidence of harm to the fetus due to mesna. The incidence of malformations in human pregnancies has not been established for MESNEX.  All pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations and 15 to 20% for pregnancy loss. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d15a8a67-9c49-417f-98df-cc897aa71b51"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether mesna or dimesna is excreted in human milk. Benzyl alcohol present in maternal serum is likely to cross into human milk and may be orally absorbed by a nursing infant. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from MESNEX, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1c8c447f-fd76-498c-a370-52ba2e67fd6c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of MESNEX in pediatric patients have not been established. MESNEX contains benzyl alcohol (10.4 mg benzyl alcohol per mL) which has been associated with serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients. The "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome," (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates, premature, and low-birth weight infants. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Neonates, premature and low-birth weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity.  Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources [see <a href="#i4i_section_id_166aadbb-0b04-4042-b51d-41c2e1f6959d">Warnings and Precautions (5.3)</a>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ce63a95e-a4d9-4ed1-957b-be91bfaf6fe9"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of MESNEX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The ratio of ifosfamide to MESNEX should remain unchanged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea19288d-04fb-42c5-ae45-9f5364f1078d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No clinical studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of MESNEX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7037237d-7da5-485f-bd15-ea96c7de8622"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No clinical studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of MESNEX.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_1517b3c8-9cb9-480a-87e2-1f019500ce3f"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known antidote for MESNEX. </p>
<p>In a clinical trial, 11 patients received intravenous MESNEX 10 mg/kg to 66 mg/kg per day for 3 to 5 days. Patients also received ifosfamide or cyclophosphamide. Adverse reactions included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. An increased rate of these adverse reactions has also been found in oxazaphosphorine-treated patients receiving ≥80 mg MESNEX per kg per day intravenously compared with patients receiving lower doses or hydration treatment only.</p>
<p>Postmarketing, administration of 4.5 g to 6.9 g of MESNEX resulted in <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including mild <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbation, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d86c0662-2e6d-45dc-bc02-f701f2181f5c"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">MESNEX is a detoxifying agent to inhibit the <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> induced by ifosfamide. The active ingredient, mesna, is a synthetic sulfhydryl compound designated as sodium-2-mercaptoethane sulfonate with a molecular formula of C<span class="Sub">2</span>H<span class="Sub">5</span>NaO<span class="Sub">3</span>S<span class="Sub">2</span> and a molecular weight of 164.18. Its structural formula is as follows:</p>
<p>HS–CH<span class="Sub">2</span>–CH<span class="Sub">2</span>SO<span class="Sub">3</span>–Na<span class="Sup">+</span></p>
<p>MESNEX (mesna) injection is a sterile, nonpyrogenic, aqueous solution of clear and colorless appearance in clear glass multidose vials for intravenous administration. MESNEX injection contains 100 mg/mL mesna, 0.25 mg/mL edetate disodium and sodium hydroxide for pH adjustment. MESNEX Injection multidose vials also contain 10.4 mg/mL of benzyl alcohol as a preservative. The solution has a pH range of 7.5-8.5.</p>
<p>MESNEX (mesna) tablets are white, oblong, scored biconvex film-coated tablets with the imprint M4. They contain 400 mg mesna. The excipients are calcium phosphate, cornstarch, hydroxypropylmethylcellulose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, simethicone, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_88b0b644-a57b-40ef-bdcf-9b05e005f48f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_a3eac1f8-7048-4bc6-aa5e-5479aa77c4c0"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a0c239b9-1eb8-4772-aa95-8eb225b9fac0"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively. Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses. </p>
<p>Food does not affect the urinary availability of orally administered MESNEX.</p>
<p><span class="Italics">Distribution</span></p>
<p>Mean apparent volume of distribution (V<span class="Sub">d</span>) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).</p>
<p><span class="Italics">Metabolism</span></p>
<p>Analogous to the physiological cysteine-cystine system, mesna is rapidly oxidized to its major metabolite, mesna disulfide (dimesna).  Plasma concentrations of mesna exceed those of dimesna after oral or intravenous administration. </p>
<p><span class="Italics">Excretion</span></p>
<p>Following intravenous administration of a single 800 mg dose, approximately 32% and 33% of the administered dose was eliminated in the urine in 24 hours as mesna and dimesna, respectively. Mean plasma elimination half-lives of mesna and dimesna are 0.36 hours and 1.17 hours, respectively. Mesna has a plasma clearance of 1.23 L/h/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_1f6cc200-25ec-468a-b9bf-5b58e6d6b393"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_6c9b0cf2-3749-4f95-9557-bd5305f36b75"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to evaluate the carcinogenic potential of mesna.</p>
<p>Mesna was not genotoxic in the <span class="Italics">in vitro</span> Ames bacterial mutagenicity assay, the <span class="Italics">in vitro</span> mammalian lymphocyte chromosomal aberration assay or the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>No studies on male or female fertility were conducted. No signs of male or female reproductive organ toxicity were seen in 6-month oral rat studies (≤ 2000 mg/kg/day) or 29-week oral dog studies (520 mg/kg/day) at doses approximately 10-fold higher than the maximum recommended human dose on a body surface area basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_7f08a0c9-b91a-401f-b6cc-f7c7e6ef1565"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c44f7ec0-8cc5-44d2-bf40-1db1d6bd471f"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Intravenous MESNEX</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> produced by ifosfamide is dose dependent (Table 4). At a dose of 1.2 g/m<span class="Sup">2</span> ifosfamide administered daily for 5 days, 16 to 26% of the patients who received conventional uroprophylaxis (high fluid intake, alkalinization of the urine, and the administration of diuretics) developed <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (&gt;50 RBC per hpf or macrohematuria) (Studies 1, 2, and 3). In contrast, none of the patients who received mesna injection together with this dose of ifosfamide developed <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (Studies 3 and 4). In two randomized studies, (Studies 5 and 6), higher doses of ifosfamide, from 2 g/m<span class="Sup">2</span> to 4 g/m<span class="Sup">2</span> administered for 3 to 5 days, produced <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> in 31 to 100% of the patients. When MESNEX was administered together with these doses of ifosfamide, the incidence of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> was less than 7%.</p>
<a name="_RefID982DFC7C9E464D46A90459AFF5F9C023"></a><table width="100%">
<caption><span>Table 4.  Percent of MESNEX Patients Developing <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> (≥50 RBC/hpf or macrohematuria) </span></caption>
<col width="28%">
<col width="35%">
<col width="37%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Ifosfamide dose 1.2 g/m<span class="Sup">2</span> d x 5</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Ifosfamide dose 2 g/m<span class="Sup">2</span> to 4 g/m<span class="Sup">2</span> d x 3 to 5</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Conventional Uroprophylaxis (number of patients)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Standard MESNEX Intravenous Regimen (number of patients)</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Uncontrolled Studies</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 1</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16% (7/44)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">26% (11/43)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 3</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18% (7/38)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0% (0/21)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0% (0/32)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Controlled Studies</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">31% (14/46)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6% (3/46)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Study 6</p></td>
<td class="Botrule Lrule" align="center"><p class="First">100% (7/7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0% (0/8)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75a9da6e-30b0-486e-8e93-7d34b6499ab7"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Oral MESNEX</h2>
<p class="First">Clinical studies comparing recommended intravenous and oral MESNEX dosing regimens demonstrated incidences of grade 3 to 4 <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> of &lt;5%. Study 7 was an open label, randomized, two-way crossover study comparing three intravenous doses with an initial intravenous dose followed by two oral doses of MESNEX in patients with cancer treated with ifosfamide at a dose of 1.2 g/m<span class="Sup">2</span> to 2.0 g/m<span class="Sup">2</span> for 3 to 5 days. Study 8 was a randomized, multicenter study in cancer patients receiving ifosfamide at 2.0 g/m<span class="Sup">2</span> for 5 days. In both studies, development of grade 3 or 4 <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> was the primary efficacy endpoint. The percent of patients developing <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> in each of these studies is presented in Table 5.</p>
<a name="_RefID65DEAEC5A0C841AD8638893B3085F274"></a><table width="100%">
<caption><span>Table 5.  Percent of MESNEX Patients Developing Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> </span></caption>
<col width="28%">
<col width="35%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">MESNEX Dosing Regimen</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Standard Intravenous Regimen </span></p>
<p><span class="Bold">(number of patients)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Bold">Intravenous + Oral Regimen </span></p>
<p><span class="Bold">(number of patients)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Study 7</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0% (0/30)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.6% (1/28)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Study 8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3.7% (1/27)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.3% (1/23)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8611b2f4-e638-4372-a794-a5c87506daad"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">MESNEX (mesna) injection 100 mg/mL</p>
<dl>
<dt>•</dt>
<dd>NDC 0338-1305-01 1 g Multidose Vial, Box of 1 vial of 10 mL</dd>
<dt>•</dt>
<dd>NDC 0338-1305-03 1 g Multidose Vial, Box of 10 vials of 10 mL</dd>
</dl>
<p>Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]</p>
<p>MESNEX (mesna) tablets</p>
<dl>
<dt>•</dt>
<dd>NDC 67108-3565-9 400 mg scored tablets packaged in box of 10 tablets</dd>
</dl>
<p>Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_aacd77ae-3259-49c5-8da3-772f4a98ca78"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise the patient to discontinue MESNEX and seek immediate medical attention if any signs or symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, including systemic <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> occur [see <a href="#i4i_section_id_8aaa863d-6787-4cf2-9ddf-0f1abe57f5c9">Warnings and Precautions (5.1)</a>].</dd>
<dt>•</dt>
<dd>Advise the patient to take MESNEX at the exact time and in the exact amount as prescribed. Advise the patient to contact their healthcare provider if they vomit within 2 hours of taking oral MESNEX, or if they miss a dose of oral MESNEX [see <a href="#i4i_section_id_beca2f88-e0cd-4d9b-9424-b79bea6efd7d">Dosage and Administration (2.2)</a>].</dd>
<dt>•</dt>
<dd>MESNEX does not prevent <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> in all patients nor does it prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide. Advise the patient to report to their healthcare provider if his/her urine has turned a pink or red color [see <a href="#i4i_section_id_1e17fdb1-8c95-4616-b0db-a09803d3865f">Dosage and Administration (2.3)</a>].</dd>
<dt>•</dt>
<dd>Advise the patient to drink 1 to 2 liters of fluid each day during MESNEX therapy [see <a href="#i4i_section_id_1e17fdb1-8c95-4616-b0db-a09803d3865f">Dosage and Administration (2.3)</a>].</dd>
<dt>•</dt>
<dd>Advise the patient that <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms and bullous and ulcerative skin and mucosal reactions have occurred with MESNEX. Advise the patient to report to their healthcare provider if signs and symptoms of these syndromes occur [see <a href="#i4i_section_id_60147a96-f663-41b1-8040-a16f4ead3dbd">Warnings and Precautions (5.2)</a>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db7c2ace-b1a7-4b67-8e05-e8609a1becb0"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Baxter</span> Logo</span></p>
<p>MESNEX (mesna) injection manufactured by:</p>
<p>MESNEX (mesna) tablets manufactured for:</p>
<p><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA<br>For Product Inquiry  1800 ANA DRUG  (1-800-262-3784)</p>
<p>Made in Germany</p>
<p>Baxter, MESNEX, and IFEX are trademarks of Baxter International Inc.</p>
<p>Material No. HA-30-01-331</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8497c52c-d3a5-4f24-ad85-a706369d4855"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1095"></a><img alt="Representative Container Label 1g" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-01.jpg"><p class="MultiMediaCaption"> 1g Multidose Vial </p>
</div>
<p class="First"> 1g Multidose Vial </p>
<p>N (01) 1 03 0338 1305 01 4</p>
<p>Lot Number / Expires:</p>
<p>JMXXX</p>
<p>MM.JJJJ</p>
<p><span class="Bold">1 Multidose Vial     NDC 0338-1305-01</span></p>
<p>Mesnex <br><span class="Italics">(mesna) Injection</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">1g   Rx only</span></p>
<p>Each vial contains 1 gram of<br>mesna in 10 mL water.<br>1% benzyl alcohol is added as a<br>preservative.<br>See insert for dosing information.<br><span class="Bold">Store at 20° - 25°C (68° - 77°F),</span><br><span class="Bold">excursions permitted to</span><br><span class="Bold">15° - 30°C (59° - 86°F)[see USP</span><br><span class="Bold">Controlled Room Temperature]</span></p>
<p>Manufactured by:<br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p><span class="Bold">USA</span> 5564 9330 C59</p>
<div class="Figure">
<a name="id1126"></a><img alt="Representative Carton Label 1g" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-02.jpg"><p class="MultiMediaCaption"> Carton Label </p>
</div>
<p> Carton Label </p>
<p>Solwarz</p>
<p>P 186 C</p>
<p>1 Multidose Vial<br>NDC 0338-1305-01</p>
<p>MESNEX<br><span class="Italics">(mesna) Injection</span></p>
<p>1g</p>
<p>1 Multidose Vial<br>NDC 0338-1305-01</p>
<p>MESNEX <br><span class="Italics">(mesna) Injection</span></p>
<p>1g</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p>Rx only</p>
<p><span class="Bold"><span class="Italics">Baxter</span></span> Logo<br>Manufactured by<br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p><span class="Bold">HA</span>-80-01-626<br><span class="Bold">USA</span></p>
<p>Fragile:<br>Handle with care.<br>Store at 20° - 25°C<br>(68°-77°F) excursions<br>permitted to 15° - 30°C<br>(59° - 86°F) [see USP<br>Controlled Room Temperature].</p>
<p>N3 0338130501 7</p>
<p>C<br>48</p>
<p>1 Multidose Vial<br>NDC 0338-1305-01</p>
<p>MESNEX<br><span class="Italics">(mesna) Injection</span></p>
<p>1g</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p>Rx only</p>
<p><span class="Bold"><span class="Italics">Baxter</span></span> Logo<br>Manufactured by<br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p>Lot/Exp:</p>
<p>Folding Box<br>Logo<br>Can Be Recycled</p>
<p>Each vial contains 1 g mesna in<br>10 mL water, Mesnex is a sterile<br>and nonpyrogenic solution<br>containing 10%<br>sodium-2-mercaptoehane<br>sulfonate (mesna) in water for<br>injection with 0.025% edetate<br>disodium and sodium hydroxide<br>to adjust pH to 7.5 to 8.5.<br>1% benzyl alcohol is added as<br>a preservative.</p>
<p>Dosage: See package insert for<br>directions for use. Should not<br>be prescribed without thorough<br>knowledge of dose, indications<br>and toxicology as contained in<br>accompanying literature.</p>
<p>Manufactured by:<br>Baxter Healthcare Corporation<br>Deerfield, IL 60015 USA</p>
<p>Made in Germany</p>
<div class="Figure">
<a name="id1206"></a><img alt="Representative Box Label 1g panel 1 of 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-03.jpg">
</div>
<div class="Figure">
<a name="id1208"></a><img alt="Representative Box Label 1g panel 2 of 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-04.jpg">
</div>
<div class="Figure">
<a name="id1210"></a><img alt="Representative Box Label 1g panel 3 of 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-05.jpg">
</div>
<div class="Figure">
<a name="id1212"></a><img alt="Representative Box Label 1g panel 4 of 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=49fdfbc3-69f8-4706-9d11-bf60e4e7811b&amp;name=image-06.jpg">
</div>
<p>Schwarz</p>
<p>P 186 C</p>
<p><span class="Bold">10 Multidose Vials NDC 0338-1305-03</span></p>
<p>1g</p>
<p>MESNEX</p>
<p><span class="Italics">(mesna) Injection</span></p>
<p><span class="Bold"><span class="Italics">Baxter  </span></span>Logo <br>Manufactured by <br>Baxter Healthcare Corporation <br>Deerfield, IL 60015 USA</p>
<p><span class="Bold">10 Multidose Vials NDC 0338-1305-03</span></p>
<p>1g</p>
<p><span class="Bold">N3 0338130503 1</span></p>
<p>MESNEX <br><span class="Italics">(mesna) Injection</span></p>
<p>Each vial contains 1 g mesna in 10mL water. Mesnex is a sterile and nonpyrogenic solution <br>containing 10% sodium-2-mercaptoehane sulfonate (mesna) in water for injection with 0.025% <br>edetate disodium and sodium hydroxide to adjust pH to 7.5 to 8.5. 1% benzyl alcohol is added as <br>a preservative.</p>
<p><span class="Bold">Fragile: </span>Handle with care. Store at 20° - 25°C (68°-77°F) see excursions permitted to 15° - 30°C <br>(59° - 86°F) [see USP Controlled Room Temperature] U.S. Patent No 5,696, 172</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">Dosage: </span>See package insert for directions for use. Should not be prescribed without thorough <br>knowledge of dose, indications and toxicology as contained in accompanying literature.</p>
<p>Manufactured by: <br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in Germany</p>
<p>Rx only</p>
<p>HA-80-01-627 <br>USA</p>
<p><span class="Bold">10 Multidose Vials NDC 0338-1305-03</span></p>
<p>1g</p>
<p>MESNEX <br><span class="Italics">(mesna) Injection</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE</span><br><span class="Bold">10 Multidose Vials</span></p>
<p>C<br>53</p>
<p><span class="Bold">10 Multidose Vials NDC 0338-1305-03</span></p>
<p>1g</p>
<p>2639B3913</p>
<p>Lot: <br>Exp.: </p>
<p>MESNEX <br><span class="Italics">(mesna) Injection</span></p>
<p>Each vial contains 1 g mesna in 10mL water. Mesnex is a sterile and nonpyrogenic solution <br>containing 10% sodium-2-mercaptoehane sulfonate (mesna) in water for injection with 0.025% <br>edetate disodium and sodium hydroxide to adjust pH to 7.5 to 8.5. 1% benzyl alcohol is added as <br>a preservative.</p>
<p><span class="Bold">Fragile: </span>Handle with care. Store at 20° - 25°C (68°-77°F) see excursions permitted to 15° - 30°C <br>(59° - 86°F) [see USP Controlled Room Temperature] U.S. Patent No 5,696, 172</p>
<p><span class="Bold">FOR INTRAVENOUS USE</span></p>
<p><span class="Bold">Dosage: </span>See package insert for directions for use. Should not be prescribed without thorough <br>knowledge of dose, indications and toxicology as contained in accompanying literature.</p>
<p>Manufactured by: <br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>Made in Germany</p>
<p><span class="Bold">Rx only</span></p>
<p>Folding Box<br>Logo<br>Can Be Recycled</p>
<p><span class="Bold">10 Multidose Vials NDC 0338-1305-03</span></p>
<p>1g</p>
<p>MESNEX <br><span class="Italics">(mesna) Injection</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE</span><br><span class="Bold">10 Multidose Vials</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MESNEX 		
					</strong><br><span class="contentTableReg">mesna injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-1305</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MESNA</strong> (2-MERCAPTOETHANESULFONIC ACID) </td>
<td class="formItem">MESNA</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">1.04 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-1305-01</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-1305-03</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019884</td>
<td class="formItem">12/30/1988</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Baxter Healthcare Corporation (005083209)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Oncology GmbH</td>
<td class="formItem"></td>
<td class="formItem">344276063</td>
<td class="formItem">ANALYSIS(0338-1305), MANUFACTURE(0338-1305), LABEL(0338-1305), PACK(0338-1305), STERILIZE(0338-1305)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Oncology GmBH</td>
<td class="formItem"></td>
<td class="formItem">312520353</td>
<td class="formItem">API MANUFACTURE(0338-1305)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c7d5348-0e02-4efa-92c6-8daf178ebfed</div>
<div>Set id: 49fdfbc3-69f8-4706-9d11-bf60e4e7811b</div>
<div>Version: 7</div>
<div>Effective Time: 20140317</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
